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Purpose: To quantify the relationship between severity of chronic obstructive pulmonary 
disease (COPD) as expressed by Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
stage and the annual exacerbation frequency in patients with COPD.
Methods: We performed a systematic literature review to identify randomized controlled trials 
and cohort studies reporting the exacerbation frequency in COPD patients receiving usual care 
or placebo. Annual frequencies were determined for total exacerbations defined by an increased 
use of health care (event-based), total exacerbations defined by an increase of symptoms, 
and severe exacerbations defined by a hospitalization. The association between the mean forced 
expiratory volume in one second (FEV
1
)% predicted of study populations and the exacerbation 
frequencies was estimated using weighted log linear regression with random effects. The regres-
sion equations were applied to the mean FEV
1
% predicted for each GOLD stage to estimate 
the frequency per stage.
Results: Thirty-seven relevant studies were found, with 43 reports of total exacerbation fre-
quency (event-based, n = 19; symptom-based, n = 24) and 14 reports of frequency of severe 
exacerbations. Annual event-based exacerbation frequencies per GOLD stage were estimated 
at 0.82 (95% confidence interval 0.46–1.49) for mild, 1.17 (0.93–1.50) for moderate, 1.61 
(1.51–1.74) for severe, and 2.10 (1.51–2.94) for very severe COPD. Annual symptom-based 
frequencies were 1.15 (95% confidence interval 0.67–2.07), 1.44 (1.14–1.87), 1.76 (1.70–1.88), 
and 2.09 (1.57–2.82), respectively. For severe exacerbations, annual frequencies were 0.11 
(95% confidence interval 0.02–0.56), 0.16 (0.07–0.33), 0.22 (0.20–0.23), and 0.28 (0.14–0.63), 
respectively. Study duration or type of study (cohort versus trial) did not significantly affect 
the outcomes.
Conclusion: This study provides an estimate of the exacerbation frequency per GOLD stage, 
which can be used for health economic and modeling purposes.
Keywords: COPD, exacerbations, disease severity, GOLD, review, regression
Introduction
The progression of chronic obstructive pulmonary disease (COPD) is often accompa-
nied by periods of increasing symptoms, such as dyspnea, cough, and sputum produc-
tion, known as exacerbations. Exacerbations are important events because they are 
associated with an increase in mortality,1,2 significant impairment of health-related 
quality of life,3–5 and an increase in health care use and associated costs,6,7 especially 
in the event of a hospitalization.8 The exacerbation frequency is therefore an important 
outcome parameter in COPD.9,10 However, quantification of the average exacerbation 
frequency is difficult. Many studies report the exacerbation frequency, but results 
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cannot be compared directly because different definitions 
are used, exacerbations are measured in different seasons,9 
or data come from different types of studies, eg, clinical trials 
or cohort studies, each using specific inclusion criteria.10 
Use of different definitions in particular seems to have a large 
influence.
Definitions of exacerbation can be roughly divided into 
two groups, ie, symptom-based definitions and event-based 
definitions. Studies defining exacerbations as self-reported 
changes in symptoms (symptom-based definition) generally 
result in higher estimates than studies using event-based 
definitions, because they also include exacerbations which 
do not present to physicians.11 When symptoms are closely 
monitored using diaries, these “unreported” exacerbations 
are thought to account for about 50% of all exacerbations.4 
Event-based definitions use more objective criteria, such as 
a doctor’s visit, use of antibiotics and/or systemic steroids, 
or hospitalization. However, event-based definitions are 
sensitive to differences in treatment patterns between 
settings.
Another source of variation between studies is the method 
used to classify the severity of an exacerbation. Most studies 
classify exacerbations based on the treatment required, 
ie, either an increase of short-acting bronchodilator or main-
tenance medication use, additional antibiotics and/or sys-
temic corticosteroids, or hospitalization.12
Despite the difficulties in measuring exacerbations, the 
general pattern is that the frequency of exacerbations 
increases with decreasing lung function.9,10,13 However, as 
far as we know, no studies have quantified this relationship. 
The present study aimed to quantify the relationship between 
degree of airflow obstruction, expressed as the forced expira-
tory volume in one second (FEV
1
)% predicted, and the 
annual exacerbation frequency, using previously published 
data. The association was estimated separately for symptom-
based and event-based exacerbations and for total and severe 
exacerbations. Furthermore, we explored the impact of study 
duration and type of study, ie, clinical trial or cohort study, 
on this relationship. This study arose out of the need to 
estimate the average exacerbation frequency for the different 
COPD severity stages as defined by the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) that were used 
as input parameters in a COPD disease progression 
model.14,15 Because this model aims to simulate the long-term 
cost- effectiveness of interventions which successfully 
 prevent exacerbations compared with minimal care, the 
exacerbation frequency in patients receiving minimal care 
was essential.
Methods
A systematic literature review was performed to identify 
randomized controlled trials and cohort studies reporting the 
exacerbation frequency in patients receiving care as usual or 
placebo. MEDLINE, EMBASE, and the Cochrane database 
were searched using the key words “chronic obstructive pul-
monary disease”, “COPD”, or “chronic bronchitis” in combi-
nation with “exacerbat*” and the specification “cohort or 
survey” or “observation*”, or the selection “clinical trial”. 
Studies were included if they were published after 1990, had 
a follow-up of at least three months, used an event- or symp-
tom-based definition for an exacerbation, and included a group 
of patients that received either usual care or placebo (eg, the 
placebo arm of a long-acting bronchodilator trial or a combina-
tion treatment trial). Studies that included a subgroup of COPD 
patients selected based on criteria other than lung function 
were excluded (eg, studies including only patients admitted to 
hospital or patients with an acute exacerbation at baseline). 
Retrospective studies based on administrative or claims data 
were excluded because the algorithms to identify exacerbations 
in these databases are often quite different from the definitions 
used in prospective cohort studies or clinical trials. Finally, 
references of the studies that met the inclusion and exclusion 
criteria were checked.
Primary outcomes
The three main outcomes of the study were the annual 
 frequency of total exacerbations using an event-based 
 definition, the annual frequency of total exacerbations using 
a symptom-based definition, and the annual frequency of 
severe exacerbations as defined by a hospitalization. One 
study could provide more than one estimate of exacerbation 
frequency by presenting separate rates for total and severe 
exacerbations or rates based on both a symptom- and an 
event-based definition, or by presenting rates for different 
lung function classes.
Data extraction
Because the comparator arm in our model needed to reflect 
minimal care, we only extracted exacerbation data for the 
groups of patients that received either usual care or placebo. 
The following data were extracted: percentage males, mean 
age, mean lung function (FEV
1
% predicted of the study popu-
lation), follow-up duration, definition of exacerbation used 
(symptom- or event-based), and the annual exacerbation 
 frequency. If the mean FEV
1
 was only given in liters, the mean 
FEV
1
% predicted for the study population was  calculated using 
the association between the absolute value and percentage 
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predicted from other studies. If the exacerbation frequency 
was presented for different classes of the FEV
1
% predicted 
and the mean within-class FEV
1
% predicted was not specified, 
the mean FEV
1
% predicted was estimated based on the mean 
and standard deviation of the FEV
1
% predicted in the total 
population assuming a normal distribution, or it was assumed 
to be the middle FEV
1
% predicted for that specific class.
Data on the exacerbation frequency were recalculated to 
annual exacerbation rates, if necessary. The annual exacerbation 
rate was calculated by dividing the total number of exacerba-
tions by the total number of patient-years, on the assumption 
that dropouts count for half of the  follow-up time.
Data analysis
Because almost all the studies provided only point estimates 
of exacerbation rates, uncertainty around the exacerbation 
rates was estimated assuming the exacerbations to follow a 
Poisson distribution within each study. To quantify the rela-
tionship between the FEV
1
% predicted and the annual exac-
erbation frequency, weighted log linear regression analysis 
with random effects was performed. Log linear regression 
was chosen in order to symmetrize the skewed distribution 
of the exacerbation rates and approximate a normal distribu-
tion of residuals in the linear regression analysis. A random 
effect model was chosen to account for study heterogeneity. 
The logarithm of the annual exacerbation frequency was used 
as the dependent variable and the mean FEV
1
% predicted of 
the study as the independent  variable. The regression analysis 
was performed using the S-Plus routine general linear model 
for mixed-effects  models.16 Analyses were performed sepa-
rately for total event-based, total symptom-based, and severe 
exacerbations. From the resulting regression equation, the 
predicted log exacerbation rate for a specific FEV
1
% predicted 
could be calculated. Simply taking the exponential function 
of the logarithm of the exacerbation rate, in order to retrans-
form the data into a normal exacerbation rate introduces bias 
and inconsistency.17 Therefore, we have used the nonparamet-
ric smearing factor, which was calculated following the 
method of Duan et al.17,18 According to this method, the smear-
ing factor, ϕ, can be calculated as the weighted mean of the 
exponential of the differences between the logarithm of the 
observed and predicted exacerbation rates in the selected 
studies using the number of exacerbations in a study as a 
weight. This smearing factor is then multiplied by the uncor-
rected predicted exacerbation rates to find corrected predicted 
exacerbation rates for a given FEV
1
% predicted. As a result, 
the relationship between the annual exacerbation frequency 
and the FEV
1
% predicted is:
Annual exacerbation frequency =  ϕ * exp[a + b*FEV
1
% 
predicted]
whereby ϕ = smearing factor, a = intercept (estimated in the 
regression analysis), b = coefficient for FEV
1
% predicted 
(estimated in the regression analysis).
This equation was used to calculate the annual exacerba-
tion frequency in the four COPD severity stages according 
to the GOLD classification19 using a mean FEV
1
% predicted 
of 90 for mild, 65 for moderate, 42 for severe, and 23 for very 
severe COPD.20 To include the uncertainty around the smear-
ing factor jointly with the uncertainty around the regression 
coefficients, the uncertainty around the exacerbation rates per 
GOLD stage was estimated by Monte Carlo simulation, ie, 
1000 random draws were taken from the joint  distribution of 
the intercept and the coefficient for FEV
1
% predicted. For 
each combination of intercept and coefficient, the accompany-
ing smearing factor was calculated using the formula 
described above. The mean FEV
1
% predicted per GOLD stage 
was then applied to each of the 1000 combinations of inter-
cept, coefficient for FEV
1
% predicted, and smearing factor, 
resulting in 1000 estimates of the exacerbation rate per GOLD 
stage. The 2.5% and 97.5% percentiles of these 1000 estimates 
formed the 95% uncertainty interval.
Additional regression analyses were performed adding 
follow-up duration (in months) and type of study (cohort 
versus trial) to FEV
1
% predicted as dependent variables. The 
analyses were performed with Splus 8.1 (TIBCO Spotfire 
S+ Version 8.1.1 HF-001 for Microsoft Windows, 2008).
Results
The literature review identified 86 references for trials and 
cohort studies published after 1990 that seemed eligible based 
on their titles. Of these 86 references that were obtained in 
full, another 44 studies were excluded because they did not 
present exacerbation frequencies or numbers (n = 13), were 
based on a selective subgroup of COPD patients (n = 11), 
were based on a cross-sectional study or on administrative 
or claims data (n = 8), had a follow-up less than three months 
(n = 9), or used a deviant definition for an exacerbation 
(n = 3). The final 42 references referred to 37 unique studies, 
comprising 28 trials21–48 and nine cohort studies.3,6,49–55 This 
resulted in 43 estimates for the total exacerbation frequency 
and 14 estimates of the frequency of severe exacerbations. 
Of the 43 estimates of total exacerbation frequency, 19 used 
the event-based definition and 24 used the symptom-based 
definition. Characteristics of all the included studies with 
their annual exacerbation rates are presented in Table 1.
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The left three graphs in Figure 1 show the logarithm of 
the annual total and severe exacerbation frequency plotted 
against the mean FEV
1
% predicted for each study, as well 
as the estimated relationship between the two obtained from 
the regression analyses.
The estimated coefficients for the relationship between 
the mean FEV
1
% predicted and the exacerbation frequency 
are shown in Table 2. Lung function was a predictor of 
borderline significance (P = 0.053) for event-based exac-
erbations only (symptom-based, P = 0.19; severe exacerba-
tions, P = 0.50). The final association between the FEV
1
% 
predicted and the exacerbation frequency after retransform-
ing the predicted log exacerbation rate into a normal exac-
erbation rate are shown in the right three graphs in Figure 1. 
Results for the mean exacerbation frequencies for the dif-
ferent GOLD stages based on the regression equations are 
presented in Table 3. Using an event-based definition, the 
total exacerbation frequency was significantly higher in 
patients with an FEV
1
% predicted below 50% compared with 
patients having an FEV
1
% predicted above 50%.
Regression analyses with additional covariates showed 
no significant effect of duration of follow-up of the study or 
type of study (cohort versus trial). The duration of follow-up 
was of borderline significance only for total exacerbations 
using the symptom-based definition, with longer follow-up 
resulting in lower rates (Table 4).
Discussion
Although many trials and cohort studies report on the important 
outcome, ie, exacerbation frequency, the association between 
lung function and exacerbation frequency is less often inves-
tigated. The current study systematically reviewed the informa-
tion contained in the literature and combined it into an estimate 
of exacerbation frequency as a function of FEV
1
% predicted. 
The coefficient for lung function showed borderline signifi-
cance for total exacerbations using the event-based definition 
(P = 0.053), and was insignificant for total exacerbations using 
a symptom-based definition and severe exacerbations. Based 
on the estimated equation, the final estimates of the total 
exacerbation frequency per GOLD severity stage using the 
event-based definition were 0.82 for mild, 1.17 for moderate, 
1.61 for severe, and 2.10 for very severe COPD. In spite of the 
overlapping uncertainty intervals, these estimates are useful 
for health economic/modeling purposes, as long as they are 
accompanied by an appropriate uncertainty probabilistic sen-
sitivity analysis. In this way, the 95% confidence intervals vary 
substantially per GOLD stage, which would be ignored using 
a single exacerbation frequency for all GOLD stages.
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In accordance with the general finding that using the 
symptom-based definition results in higher estimates of the 
total exacerbation frequency, we found slightly higher 
estimates for mild, moderate, and severe COPD using the 
symptom-based definition compared with the event-based 
definition. However, this difference was not significant, and 
seemed to get smaller with increasing severity of COPD. 
We also did not see an effect of follow-up duration. The 
mean follow-up in the studies in this review was 14 months, 
ranging from three to 36 months.
The study had a couple of limitations and strengths. 
A reason why the relationship between lung function and 
20
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Figure 1 Left graphs: Logarithm of the annual total or severe exacerbation frequency plotted against the mean forced expiratory volume in one second (FeV1)% predicted of 
the study, line = estimated relationship obtained from the log-linear regression. right graphs: Annual total or severe exacerbation frequency plotted against the mean FeV1% 
predicted of the study, line = relationship based on the retransformed exacerbation rates using the smearing factor.
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exacerbation frequency in our study was relatively weak may 
be our use of published data. Regression on study summary 
estimates, as done in this study, has substantially less power 
than regression on patient-level data.56 It is likely that varia-
tion in lung function across studies is lower than variation 
in lung function across patient-level data within studies. By 
plotting the mean exacerbation frequency against the mean 
FEV
1
% predicted of a particular study, the within-study 
variation was not accounted for. Thus, a limitation of our 
study was that the heterogeneity in mean lung function 
between the studies in our review was relatively limited, 
especially for severe exacerbations. The majority of studies 
had a mean FEV
1
% predicted between 35% and 60%, and 
studies with a very low (,30%) and a very high mean FEV
1
% 
predicted (.80%) were scarce or completely lacking. How-
ever, using a systematic review, the current study reflects the 
full evidence present in the current literature. This is prefer-
able to using a single patient-level study, which may be 
biased towards the specific population under study.
Another limitation may be that most of the data were 
obtained from patients participating in clinical trials each 
using specific inclusion criteria. We included data from 
28 clinical trials including 6780 patients and nine cohort 
studies including 2211 patients. Trial populations may be 
biased towards a lower exacerbation frequency because they 
include clinically stable patients with no other major comor-
bidities and who are motivated to participate in a trial. 
However, an overestimation could also be possible, because 
a large number of trials included only patients with at least 
one or two exacerbations in the year before inclusion. The 
cohort studies included in our review used similar inclusion 
criteria as the trials, and therefore probably included similar 
patient populations. No systematic difference in exacerbation 
rate was found between the cohort studies and trials. How 
these compare with the COPD population seen in daily 
practice is difficult to determine. One indication may be found 
in large retrospective database analyses.57–59 These studies 
used event-based definitions and usually found lower 
 exacerbation frequencies than our study, which gives us 
confidence that we did not underestimate exacerbation 
frequencies.
Exacerbations depend on the season, and are more likely 
to occur in winter.3 Therefore, according to current 
recommendations,12 studies need to have a follow-up of at 
least 12 months or recruitment should be spread  throughout 
the year to give reliable estimates of exacerbation frequency. 
A strength of our study is that the majority of trials (89%) 
had a follow-up of at least six months and 65% had a fol-
low-up of at least one year. Conversion of exacerbation rates 
from studies with a follow-up duration of less than 12 months 
to annual rates may have overestimated or underestimated 
the exacerbation frequency. However, we did not find a sig-
nificant difference between studies with a follow-up duration 
shorter and longer than 12 months.
Table 2 Estimates regression coefficients, covariance, and smearing factors for the relation between FEV1% predicted and annual 
exacerbation rate described as: annual exacerbation frequency = ϕ * exp[ a + b * FeV1% predicted]
Total exacerbations:  
Event-based definition#
Total exacerbations:  
Symptom-based definition#
Severe exacerbations#
Intercept: a 1.181 (0.351), P = 0.004 0.981 (0.364), P = 0.01 -1.043 (0.904), P = 0.27
Coefficient FEV1% predicted: b -0.014 (0.007), P = 0.053 -0.009 (0.007), P = 0.19 -0.013 (0.020), P = 0.51 
Covariance intercept and coefficient -0.00227 -0.00227 -0.0176
smearing factor: ϕ 0.893 0.960 1.072
Note: #Values are mean (standard error of the mean), P value.
Abbreviation: FeV1, forced expiratory volume in one second.
Table 3 estimated annual exacerbation frequency per gOLD stage based on the regression equations (95% uncertainty interval)
GOLD stage Mean FEV1%  
predicted
Total exacerbations:  
Event-based definition
Total exacerbations:  
Symptom-based  
definition
Severe  
exacerbations
I: Mild COPD (FeV1% pred $ 80%) 90 0.82 (0.46–1.49) 1.15 (0.67–2.07) 0.11 (0.02–0.56)
II: Moderate COPD (50% # FeV1% pred , 80%) 65 1.17 (0.93–1.50) 1.44 (1.14–1.87) 0.16 (0.07–0.33)
III: severe COPD (30% # FeV1% pred , 50%) 42 1.61 (1.51–1.74) 1.76 (1.70–1.88) 0.22 (0.20–0.23)
IV: Very severe COPD (FeV1% pred , 30%) 23 2.10 (1.51–2.94) 2.09 (1.57–2.82) 0.28 (0.14–0.63)
Abbreviations: FeV1, forced expiratory volume in one second; COPD, chronic obstructive pulmonary disease; gOLD, global initiative for chronic obstructive lung disease; 
pred, predicted.
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To validate the exacerbation frequencies found in our 
study, they may be compared with the limited patient-level 
data on the exacerbation frequency specified by  subgroup 
of lung function. The cohort study of Andersson et al, which 
was included in the review, was the only study providing 
estimates for four COPD severity stages, using almost the 
same cutoff points for the stages as the GOLD classification.6 
The study used an event-based definition for exacerbations, 
and found an annual exacerbation frequency of 0.67 for 
mild, 0.70 for moderate, 1.06 for severe, and 2.56 for very 
severe COPD, which was somewhat lower than our esti-
mates, except for very severe COPD. Vestbo et al reported 
on the exacerbation frequencies in several cohort studies 
and placebo arms of trials in relation to the FEV
1
% pre-
dicted, and also found exacerbation frequencies below 1.0 
for patients with an FEV
1
% predicted above 50%. The aver-
age values for exacerbations for patients with an FEV
1
% 
predicted between 40% and 50% ranged between 1.0 
and 1.5, which was comparable with our results.10 Burge 
et al showed the number of exacerbations per year in the 
placebo arm of the ISOLDE (Inhaled Steroids in Obstruc-
tive Lung Disease) trial using an event-based definition and 
specified the frequency for three lung function categories, 
ie, ,1.25, 1.25–1.54, and .1.54 liters (about comparable 
with ,45%, 44%–55%, and .55% predicted). Below 45% 
predicted a mean of 2.6 exacerbations was found, while 
above .55%, the average value was about 1.2.13 From the 
aforementioned studies, the general picture seems to be 
that, above 50% predicted, the total annual exacerbation 
frequency is around or slightly below 1.0, while below 
40%–45% predicted, the exacerbation rate increases sig-
nificantly to about two or more exacerbations per year. The 
results of our study showed the same picture.
In conclusion, the current study provides an estimate of 
the association between annual exacerbation frequency and 
FEV
1
% predicted in COPD, based on aggregated summary 
data from individual studies. Results were in line with the few 
studies reporting on this relationship using patient-level data. 
The resulting GOLD stage-specific exacerbation  frequencies 
show overlapping uncertainty intervals, and hence any 
analysis based on these rates should be accompanied by a 
proper sensitivity analysis.
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